ZBTB22

Across TCGA pan-cancer cohorts, ZBTB22 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ZBTB22 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher ZBTB22 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZBTB22 expression acts as an unfavorable survival marker.

MESO, COAD, and OV are the cancer types where ZBTB22 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.077	0.580	<.001	42	view →
COAD	OS	Median	All	0.149	0.807	<.001	27	view →
OV	OS	Median	II,III,IV	0.330	0.843	.002	18	view →
LUSC	OS	Median	II,III,IV	0.043	0.781	<.001	10	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ZBTB22–MESO (OS)

Open the MESO breakdown →